US · IMMP · BIOTECHNOLOGY
Immutep Limited (IMMP) intrinsic value and stock valuation
$3.11as of 2026-11-21 · Mkt cap 56.86M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Immutep Limited DCF and intrinsic value
InvestorsCraft values IMMP with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IMMP’s statements →
Immutep Limited Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Candel Therapeutics, Inc. (CADL) $5.04
- Allogene Therapeutics, Inc. (ALLO) $0.63
- Achieve Life Sciences, Inc. (ACHV) $6.78
- Cabaletta Bio, Inc. (CABA) $0.94
- Editas Medicine, Inc. (EDIT) $1.64
- Vanda Pharmaceuticals Inc. (VNDA) $3.45
- Entrada Therapeutics, Inc. (TRDA) $4.35
- Capricor Therapeutics, Inc. (CAPR) $7.59
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.04M | $3.84M | $3.51M | $170K | $3.86M |
| Operating income | -$-126.42M | -$-88.1M | -$-77.69M | -$-33.94M | -$-31.68M |
| Net income | -$-61.43M | -$-42.72M | -$-39.9M | -$-32.21M | -$-29.9M |
| EPSd | -$-421.97K | -$-355.67K | -$-443.04K | -$-373.54K | -$-494.79K |
| Operating cash flow | -$-62.05M | -$-34.82M | -$-35.88M | -$-30.23M | -$-17.64M |
| Capital expenditure | -$-50K | -$-930K | -$-50K | -$-20K | -$-20K |
| Free cash flow | -$-62.1M | -$-35.75M | -$-35.93M | -$-30.25M | -$-17.66M |
| Total assets | $157M | $201.6M | $147.5M | $102.2M | $82M |
| Total debt | $1.63M | $1.59M | $1.23M | $1.73M | $2.82M |
| Net debt | -$-65.78M | -$-160.2M | -$-122.19M | -$-78.26M | -$-57.31M |
| Total equity | $143.6M | $189.5M | $136.5M | $94.1M | $73.3M |
| Cash and short-term investments | $129.7M | $181.9M | $123.4M | $80M | $60.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.04M | $3.84M | $3.51M | $170K | $3.86M |
| Cost of revenue | $61.4M | $41.6M | $2.06M | $2.06M | $17.2M |
| Gross profit | -$-56.37M | -$-37.7M | $1.44M | -$-1.89M | -$-13.37M |
| Research and development expenses | $61.4M | $41.6M | $28.8M | $31.3M | $17.2M |
| Selling, general and administrative expenses | $8.64M | $8.85M | $14.1M | $7.21M | $6.28M |
| Other expenses | $0.00 | $0.00 | $2.06M | -$-6M | -$-5.22M |
| Operating expenses | $70.1M | $50.4M | $44.9M | $32.6M | $18.3M |
| Cost and expenses | $131.5M | $92M | $81.2M | $34M | $35.5M |
| Interest income | $5.25M | $3.88M | $940K | $220K | $110K |
| Interest expense | $20K | $30K | $20K | $90K | $10K |
| Depreciation and amortization | $2.13M | $2.01M | $1.86M | $1.84M | $1.89M |
| Ebitda | -$-62.88M | -$-44.54M | -$-39.57M | -$-31.87M | -$-17.77M |
| Operating income | -$-126.42M | -$-88.1M | -$-77.69M | -$-33.94M | -$-31.68M |
| Total other income/expenses, net | $65M | $45.4M | $37.8M | $1.63M | $1.77M |
| Income before tax | -$-61.43M | -$-42.72M | -$-39.9M | -$-32.21M | -$-29.9M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-61.43M | -$-42.72M | -$-39.9M | -$-32.21M | -$-29.9M |
| Weighted average shares outstanding | $145.6M | $120M | $90.1M | $86.2M | $60.4M |
| Weighted average diluted shares outstanding | $145.6M | $120.1M | $90.1M | $86.2M | $60.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $129.7M | $181.9M | $123.4M | $80M | $60.1M |
| Net receivables | $10K | $7.56M | $7.97M | $8.37M | $6.12M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | -$-5.66M |
| Total current assets | $149.1M | $191.4M | $135M | $90.8M | $68.4M |
| Property, plant and equipment, net | $570K | $680K | $470K | $310K | $310K |
| Goodwill and intangible assets | $7.2M | $8.24M | $9.49M | $10.6M | $12.9M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $7.89M | $10.2M | $12.5M | $11.4M | $13.6M |
| Total assets | $157M | $201.6M | $147.5M | $102.2M | $82M |
| Accounts payable | $5.53M | $3.79M | $5.45M | $2.87M | $1.82M |
| Short-term debt | $1.31M | $230K | $190K | $170K | $420K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $12.8M | $10.5M | $9.77M | $6.41M | $5.34M |
| Long-term debt | $310K | $1.36M | $1.04M | $1.56M | $2.61M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $590K | $1.57M | $1.21M | $1.68M | $3.42M |
| Capital lease obligations | $520K | $630K | $390K | $280K | $290K |
| Total liabilities | $13.4M | $12.1M | $11M | $8.09M | $8.76M |
| Common stock | $535.1M | $542.1M | $446.3M | $367.4M | $313.4M |
| Retained earnings | -$-444.08M | -$-382.65M | -$-339.93M | -$-302.34M | -$-274.64M |
| Accumulated other comprehensive income (loss) | $52.7M | $30.1M | $30.1M | $29M | $34.5M |
| Total equity | $143.6M | $189.5M | $136.5M | $94.1M | $73.3M |
| Total investments | $62.3M | $20.1M | $0.00 | $0.00 | $0.00 |
| Total debt | $1.63M | $1.59M | $1.23M | $1.73M | $2.82M |
| Net debt | -$-65.78M | -$-160.2M | -$-122.19M | -$-78.26M | -$-57.31M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-61.43M | -$-42.72M | -$-39.9M | -$-32.21M | -$-29.9M |
| Depreciation and amortization | $2.39M | $2.26M | $2.06M | $2.06M | $2.07M |
| Stock-based compensation | $1.16M | $1.8M | $2M | $1.49M | $1.7M |
| Change in working capital | -$-8.54M | $3.46M | $760K | -$-1.56M | -$-1.99M |
| Accounts receivable | -$-2.52M | $600K | -$-1.61M | -$-2.25M | -$-2.83M |
| Inventory | $0.00 | $0.00 | $0.00 | $810K | $0.00 |
| Accounts payable | $0.00 | $0.00 | $3.27M | $1.44M | $1.38M |
| Net cash provided by operating activities | -$-62.05M | -$-34.82M | -$-35.88M | -$-30.23M | -$-17.64M |
| Investments in property, plant and equipment | -$-50K | -$-930K | -$-50K | -$-20K | -$-20K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-38.53M | -$-21.02M | -$-30K | -$-20K | -$-20K |
| Common stock issued | -$-160K | $100.2M | $80.1M | $53M | $43.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-530K | $95.2M | $76M | $50.3M | $52.7M |
| Net change in cash | -$-94.38M | $38.4M | $43.4M | $19.4M | $34.3M |
| Cash at end of period | $67.4M | $161.8M | $123.4M | $80M | $60.6M |
| Operating cash flow | -$-62.05M | -$-34.82M | -$-35.88M | -$-30.23M | -$-17.64M |
| Capital expenditure | -$-50K | -$-930K | -$-50K | -$-20K | -$-20K |
| Free cash flow | -$-62.1M | -$-35.75M | -$-35.93M | -$-30.25M | -$-17.66M |
Line items
Line items
Line items
About Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
- CEO
- Marc Voigt
- Employees
- 53
- Beta
- 2.27
Explore
Frequently asked questions
What is the intrinsic value of Immutep Limited (IMMP)?
Immutep Limited (IMMP) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is IMMP undervalued?
IMMP trades at a price of $3.11 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.